易明医药
(002826)
| 流通市值：33.49亿 | | | 总市值：36.63亿 |
| 流通股本：1.74亿 | | | 总股本：1.91亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 292,524,500.97 | 427,398,137.38 | 227,892,039.74 | 194,177,483.67 |
| 应收票据及应收账款 | 38,557,187.08 | 52,374,607.9 | 86,620,276.62 | 104,418,273.17 |
| 其中：应收票据 | 342,000 | 12,866,464.7 | 202,395.99 | 299,217.82 |
| 应收账款 | 38,215,187.08 | 39,508,143.2 | 86,417,880.63 | 104,119,055.35 |
| 预付款项 | 24,099,863.43 | 1,886,974.73 | 6,328,287.81 | 22,640,758.35 |
| 其他应收款合计 | 2,776,904.81 | 2,969,762.96 | 3,958,153.2 | 3,795,647.43 |
| 存货 | 33,126,650.41 | 41,050,668.84 | 39,648,652.02 | 33,862,829.59 |
| 其他流动资产 | 2,311,520.83 | 1,932,985.52 | 214,401.71 | 1,120,144.24 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 593,396,627.53 | 527,613,137.33 | 524,661,811.1 | 490,015,136.45 |
| 非流动资产: | | | | |
| 长期应收款 | 11,130,165.12 | 11,145,980.74 | - | - |
| 长期股权投资 | - | - | 41,692,322.3 | 42,652,631.21 |
| 其他非流动金融资产 | 3,610,136.94 | 3,615,266.83 | - | - |
| 固定资产 | 339,917,570.96 | 344,627,986.11 | 336,974,927.1 | 340,374,418.77 |
| 在建工程 | 169,635.75 | - | 7,543,471.33 | 6,832,258.94 |
| 无形资产 | 19,759,021.71 | 20,695,162.7 | 21,758,630.74 | 23,076,752.84 |
| 商誉 | 16,668,928.89 | 16,668,928.89 | 16,668,928.89 | 16,668,928.89 |
| 递延所得税资产 | 1,858,902.45 | 2,004,272.27 | 4,064,589.08 | 3,857,504.71 |
| 其他非流动资产 | - | 98,500 | 120,000 | 269,275 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 393,114,361.82 | 398,856,097.54 | 428,822,869.44 | 433,731,770.36 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 986,510,989.35 | 926,469,234.87 | 953,484,680.54 | 923,746,906.81 |
| 流动负债: | | | | |
| 短期借款 | 35,300,443.1 | 22,819,445.17 | 8,280,000 | 11,000,000 |
| 应付票据及应付账款 | 109,135,397.93 | 103,512,736.32 | 151,786,589.31 | 120,604,050.87 |
| 应付账款 | 109,135,397.93 | 103,512,736.32 | 151,786,589.31 | 120,604,050.87 |
| 合同负债 | 985,177.42 | 3,152,408.11 | 1,866,447.62 | 3,052,821.09 |
| 应付职工薪酬 | 10,887,120.48 | 13,439,297.29 | 8,852,731.42 | 7,491,270.7 |
| 应交税费 | 9,766,370.26 | 7,321,177.4 | 10,322,328.09 | 7,471,630.51 |
| 其他应付款合计 | 47,199,088.18 | 24,462,526.61 | 27,396,053.94 | 31,378,999.67 |
| 其他流动负债 | 128,073.06 | 409,813.06 | 242,397.16 | 396,866.69 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 213,401,670.43 | 175,117,403.96 | 208,746,547.54 | 181,395,639.53 |
| 非流动负债: | | | | |
| 递延收益 | 5,574,137.01 | 5,775,502.47 | 5,976,867.93 | 6,178,233.39 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 5,574,137.01 | 5,775,502.47 | 5,976,867.93 | 6,178,233.39 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 218,975,807.44 | 180,892,906.43 | 214,723,415.47 | 187,573,872.92 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 190,677,750 | 190,677,750 | 190,677,750 | 190,677,750 |
| 资本公积 | 233,327,967.03 | 232,661,362.96 | 232,661,362.96 | 232,661,362.96 |
| 减:库存股 | 48,325,124.75 | 50,025,670.68 | 50,025,670.68 | 50,025,670.68 |
| 其他综合收益 | 903,100.27 | 969,277.05 | -249,215.43 | 557,509.59 |
| 专项储备 | 6,840,315.85 | 6,110,992.17 | 5,353,781.4 | 4,660,042.74 |
| 盈余公积 | 21,861,741.5 | 21,861,741.5 | 20,860,834.15 | 20,860,834.15 |
| 未分配利润 | 355,542,076.29 | 336,748,224.36 | 333,639,724.85 | 331,466,494 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 760,827,826.19 | 739,003,677.36 | 732,918,567.25 | 730,858,322.76 |
| 少数股东权益 | 6,707,355.72 | 6,572,651.08 | 5,842,697.82 | 5,314,711.13 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 767,535,181.91 | 745,576,328.44 | 738,761,265.07 | 736,173,033.89 |
| 负债和股东权益合计 | 986,510,989.35 | 926,469,234.87 | 953,484,680.54 | 923,746,906.81 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-30 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |